The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) met from 23 to 26 March 2026. During this meeting, the CHMP recommended five new medicines for approval. Among them are Adstiladrin (nadofaragene firadenovec) for the treatment of adults, Imdylltra (tarlatamab) for the treatment of advanced-stage small cell lung cancer, Joenja (leniolisib) for the treatment of activated phosphoinositide 3 and Zepzelca (lurbinectedin) as a maintenance treatment for adult patients. The CHMP also issued a positive recommendation for the new hybrid medicine Borapemide I. In addition, the CHMP recommended the extension of therapeutic indications for several existing medicines, including Besponsa, Capvaxive, Hetronifly, Hympavzi, Imcivree, Lojuxta, Mekinist, the respiratory syncytial virus vaccine, Namuscla, Retsevmo and Tafinlar. The committee also reviewed Hetlioz and issued a recommendation for Tecovirimat SIGA.